Lazard, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 30, 2026, discloses that Lazard, Inc. (the "Company") has entered into a definitive Sale and Purchase Agreement to acquire 100% of the issued share capital of Campbell Lutyens Holdings Limited ("Campbell Lutyens"). Campbell Lutyens is described as a leading global independent private capital advisor specializing in fund placement, secondary advisory, and GP capital advisory services.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the acquisition rather than the Company's periodic operating results. The aggregate consideration for the acquisition is structured as follows:
- Initial Consideration: $460 million, subject to adjustments for cash, debt, and working capital. This is expected to be primarily satisfied in Lazard common stock based on a reference price of $46.50 per share.
- Deferred Consideration: $115 million payable on the second anniversary of closing.
- Earn-Out Consideration: Up to $85 million contingent on revenue-growth targets for the combined business through 2030.
- Total Potential Consideration: Up to $660 million.
The filing does not provide specific revenue, profit, cash flow, or margin data for Lazard or Campbell Lutyens for the reporting period.
Material Changes and Conditions
The transaction represents a material change in the Company's business scope through the acquisition of a private capital advisory firm. Key conditions and terms include:
- Regulatory Approvals: Closing is conditional on certain regulatory approvals, including the U.K. Competition and Markets Authority.
- Termination Fee: If the Company terminates the agreement due to the failure to satisfy the U.K. regulatory condition, it must pay a termination fee of $50 million.
- Share Issuance Cap: The maximum number of common shares issuable is capped at the lesser of 19.99% of the voting power or the number of outstanding shares as of closing.
- Lock-Up Provisions: A portion of the initial consideration shares will be subject to contractual lock-up restrictions lapsing over three years.
- Deadline: The agreement may be terminated if closing has not occurred by March 31, 2027.
Outlook, Risks, and Contingencies
Management anticipates the acquisition will expand capabilities in the private markets industry. However, the filing highlights significant risks and contingencies:
- Completion Risk: The transaction may not close on expected terms or at all due to regulatory failures or other closing conditions.
- Integration Risk: Potential difficulties, delays, or higher-than-expected costs in integrating Campbell Lutyens' operations and personnel.
- Market Conditions: Adverse economic conditions or changes in M&A and fundraising activity could impact the expected benefits.
- Forward-Looking Statements: Projections regarding financial performance and strategic benefits are subject to known and unknown risks and uncertainties.
Investor Verification Checklist
- Verify the status of required regulatory approvals, specifically from the U.K. Competition and Markets Authority.
- Confirm the final closing price of Lazard common stock to determine the exact number of shares to be issued for the $460 million initial consideration.
- Review the specific revenue-growth targets and measurement periods for the $85 million earn-out.
- Assess the potential dilution impact, noting the 19.99% cap on share issuance and the possibility of cash or loan note settlements for excess value.
- Monitor the March 31, 2027, deadline for closing to evaluate the risk of termination and the associated $50 million fee liability.